Emcure Pharmaceuticals Ltd reported a strong performance for the first quarter ended June 30, 2025, registering a 15.7 per ...

The latest announcement is out from Emcure Pharmaceuticals Limited ( (IN:EMCURE) ). Emcure Pharmaceuticals Limited announced the scheduling of its 44th Annual General Meeting (AGM) on August 28, 2025 ...

Emcure Pharmaceuticals posts a 40.76% rise in Q1 profit after tax to ₹215 crore, driven by solid operational performance ...

Emcure Pharmaceuticals reported sales of 21,005.37, net income of 2,069.53, and EPS of 11.10 for the latest quarter., net income of 2,069.53, and EPS of 11.10 for the latest quarter.

Revenue from operations in the quarter under review stood at Rs 2,101 crore as against Rs 1,815 crore in the year-ago period.

Emcure Pharmaceuticals reported a 44% rise in Q1 net profit to ₹207 crore, driven by robust international growth and margin improvement. Revenue grew 15.7%.

Emcure Pharmaceuticals partners with Sanofi India to distribute and promote oral anti-diabetic products in India.

Emcure Pharmaceuticals IPO listing date has been scheduled for tomorrow (Wednesday, July 10). IPO GMP is heading upward and is expected to have a solid listing based on the actions of the past 13 ...

Generic drugmaker Emcure Pharmaceuticals convinced a federal court in Seattle, Washington, on Monday to throw out a lawsuit that accused it of stealing trade secrets from biopharma company HDT Bio ...

Emcure Pharmaceuticals IPO subscription status: The market as a whole was strong, and investors responded well to Emcure Pharmaceuticals' initial public offering (IPO) on the second bidding day ...

Emcure Pharmaceuticals IPO GMP Read more: How much you can save from Uttar Pradesh's waiver of registration fee on hybrid cars Ahead of the listing, Emcure Pharma IPO GMP on July 9 is +352 which ...

Seattle biopharma company HDT Bio Corp has sued Indian generic drugmaker Emcure Pharmaceuticals Ltd in U.S. court for allegedly stealing RNA-delivery technology to use in its COVID-19 vaccine.